OpenAI and Capco Announce Services Partnership to Accelerate the Transformation of the Global Financial Services and Energy Sectors
Global management and technology consultancy Capco, a Wipro company, has joined OpenAI’s Beta Services Partner Program, providing Capco with priority access to the very latest AI innovation. Capco and OpenAI will collaborate to solve complex client problems and deploy scalable solutions, positioning Capco as a trusted AI partner to financial services and energy clients worldwide.
Through the services partnership, Capco gains early access to OpenAI’s technology, technical support, solution architects, and training resources. OpenAI will leverage Capco’s 25+ years of global transformation expertise and proven delivery experience across the financial services and energy sectors. Together, Capco and OpenAI will explore innovative solutions to tackle the most significant challenges confronting financial services and energy clients today.
The opportunities for AI-led innovation are significant, ranging from enhanced product design to operational change and regulatory compliance, to employee productivity and hyper-personalized customer experiences.
One example of an existing offering built by Capco’s AI Lab using OpenAI’s technology is Compliance Assist. Compliance Assist, part of the Capco Smart Suite range of AI-powered solutions and services, helps banks proactively scan upcoming regulatory changes and automatically identify the changes required to a firm’s processes and procedures – saving thousands of hours of work.
Financial services firms must ensure that their regulatory-related policies and processes are always compliant, or risk reputational damage or financial penalties. For multinational banks in particular, this requires time consuming work to update hundreds of policies, procedures and reports. When adopted recently by a leading European retail bank, Compliance Assist reduced the workload by 80% and halved the time needed to assess the impact across policies, procedures and controls.
An early focus of the new collaboration between Capco and OpenAI will be on exploring how OpenAI’s GPT-5 latest offering of improved contextual understanding and fine-tuning can further automate and streamline processes, moving from reactive to proactive control and compliance.
Anne-Marie Rowland, CEO of Capco, said: “We are delighted to announce our new services partnership with OpenAI. Capco delivers bold, innovative solutions that empower our clients to lead with confidence and outpace the market. This new services partnership firmly positions us at the leading edge of AI innovation, allowing us to take our AI offerings to the next level.
“We are now even more strongly positioned to deliver flexible, scalable AI-powered solutions that accelerate our clients’ ambitions – helping them driving faster, smarter, and more impactful outcomes. Having infused AI across our own business, we have seen up close the transformative impact and benefits that can be achieved.”
Chris Probert, Partner and Global Head of Data, Analytics & AI at Capco, said: “Capco has always been committed to offering pragmatic generative and agentic solutions that drive AI-led, customer-centric transformation in a scalable and repeatable fashion. Opening the way to deeper collaboration with the OpenAI team, this services partnership allows us to pursue our shared vision of building custom AI models and tools that reimagine and accelerate the future evolution of our clients’ businesses.”
Ksenia Chumachenko, Head of GTM Partnerships at OpenAI, said: “We’re excited to partner with Capco to bring the power of OpenAI’s technology to financial services and energy firms worldwide. Their deep sector expertise and strong client relationships make them a valued services partner as we help institutions unlock new value with AI.”
About Capco
Capco, a Wipro company, is a global management and technology consultancy redefining transformation across the energy and financial services industries. Capco leverages the power of AI and our deep domain expertise to help our clients move faster, make smarter decisions, and drive greater impact. Our award-winning Be Yourself at Work culture and diverse talent drive bold, forward-thinking ideas and lasting change. To learn more, visit www.capco.com or follow us on LinkedIn, Instagram, Facebook, and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251117497238/en/
Contacts
Media Contact
Gregory
capco@gregoryagency.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Positive Phase 3 Results Support ZIIHERA ® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA ® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 13:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction, and esophagus. Both ZIIHERA plus TEVIMBRA and chemotherapy and ZIIHERA plus chemotherapy demonstrated clinically meaningful and highly statistically significant improvements in progression-free survival (PFS) compared to the control arm, trastuzumab plus chemotherapy. ZIIHERA plus TEVIMBRA and chemotherapy also demonstrated clinically meaningful and statistically significant improvements in overall survival (OS), and ZIIHERA plus chemotherapy demonstrated a clinically meaningful eff
Global Winners of the 2025–2026 World Branding Awards Announced at First-Ever Japan Ceremony17.11.2025 12:43:00 EET | Press release
Now in its 20th edition, the World Branding Awards continues to spotlight the world’s most impactful and trusted brands. This year, over 1,092 brands from 66 countries were nominated as “Brand of the Year”, with less than 100 declared Winners across Global, Regional, and National tiers. The World Branding Awards Ceremony stepped outside London for the first time, bringing its global presence to the Osaka City Museum of Fine Arts. The 2025–2026 edition welcomed over 80 international guests and was presented by the acclaimed Allie Sakakibara. The evening was further elevated by a keynote presentation from Miho Noguchi, who shared insights on building emotional resonance through immersive brand experiences. Global Tier winners celebrated their outstanding branding excellence across various industries, including IKEA (Sweden), Lurpak (Denmark), Marriott International (United Kingdom), Nike (USA), Sennheiser (Germany), and Yakult (Japan). These brands consistently demonstrated strength, inf
Henlius and Organon Announce US FDA Approval of POHERDY ® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US17.11.2025 12:30:00 EET | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.1 POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality and potentially more affordable biologic therapies for patients with certain HER2-positive breast cancers.2 "Expanding access to treatments for diseases that disproportionately impact women, including breast cancer, the most common cancer among women in the US excluding skin cancer, is at the core of our mission,” said Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon.3 “Not only is POHERDY the first approved biosimilar to PERJETA in the US, but its approval also builds
WEX ® Unlocks Access to 20,000+ Tesla Superchargers Across Europe17.11.2025 12:15:00 EET | Press release
WEX® (NYSE: WEX), the global commerce platform that simplifies the business of running a business, today announced integration with the Tesla Supercharger network, adding over 20,000 fast-charging points across 1,500+ locations to its platform. The move significantly expands charging options for WEX’s customers, particularly in areas where high-power charging has been limited or expensive. By bringing Tesla Superchargers into their ecosystem, WEX gives drivers access to competitively priced fast charging with speeds up to 250 kW, increasing availability of high-power charging stations by 10%. WEX customers already use the EV Driver by WEX app to charge at over 1 million charging points throughout Europe. Now, they can access Tesla Superchargers with the same seamless experience: comparing real-time pricing across all networks, planning optimal routes, tracking sessions, and managing payments in one unified platform - regardless of the charging network they choose. “Providing access to
Global Cement Industry Reports 25% CO 2 Intensity Reduction and Calls for Urgent Government Action to Accelerate Net Zero Mission17.11.2025 12:00:00 EET | Press release
The extensive decarbonisation work being carried out by the global cement and concrete industry to cut CO₂ emissions is set out in a new global report launched at COP30 in Belem, Brazil. The report details latest industry data showing that the sector is making progress, and also emphasises the need for urgent global government input to help accelerate action. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117920702/en/ GCCA Cement and Concrete Industry Net Zero Action and Progress Report The report finds that the industry has reduced the CO₂ intensity of cementitious products by 25% across the globe since 1990, and also sets out a series of policy recommendations that can pave the way for faster reductions. Dominik von Achten GCCA President and Chairman of the Managing Board of Heidelberg Materials said: "Our industry is collaborating and innovating across every aspect of our manufacturing – finding new ways to work and d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom